Elsevier and US National Cancer Institute Implement Reciprocal Linking Between Research Articles and Datasets
Articles on ScienceDirect and scientific and biomedical research data within NCI’s cancer Nanotechnology Laboratory portal are now reciprocally linked
Amsterdam, July 9, 2015
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the US National Cancer Institute (NCI), a world-leading institute for cancer research, today announced that they have implemented two-way linking between research articles on ScienceDirect and datasets stored in NCI’s cancer Nanotechnology Laboratory (caNanoLab) data portal. The NCI is part of the US National Institutes of Health (NIH).
caNanoLab provides facilities for the submission and retrieval of information on well-characterized nanomaterials, including composition, physico-chemical and in vitro/in vivo characterizations, and protocols. This resource, developed by NCI, is designed to support information sharing across the international biomedical nanotechnology research community to expedite and validate the use of nanotechnology in biomedicine. As such, caNanoLab provides publically accessible cancer nanotechnology data and enables the sharing of non-public data between established collaboration groups.
Reciprocal linking between data portals and scientific literature ensures that the core research output – research data – is easy to find and can be reused by other researchers who want to build upon previous work. Scientific and biomedical research datasets stored in the caNanoLab data portal are currently accessible through research articles from ten Elsevier journals available on ScienceDirect and vice versa - the research articles can also be accessed from the datasets in caNanoLab.
Dr. Stephanie Morris, Program Director in NCI’s Office of Cancer Nanotechnology Research, said, “As part of our mission, NCI supports efforts to make research data more accessible to scientists everywhere. Direct linking between research articles and the underlying nanomaterial characterization data is an opportunity to increase communication between scientists. Every time we make it easier and faster to obtain high-quality and complete datasets for experimental reuse and reproduction, it is a win-win for the entire research community.”
Dr. Kinam Park, Editor-in-Chief of the Journal of Controlled Release (JCR), said, “The number of publications made in the cancer nanotechnology area is so large that information sharing has become difficult, even with the help of search engines. caNanoLab is an exciting first step in achieving a free flow of information on all nanoparticles used in cancer research. The authors of JCR will participate to add data from their publications to caNanoLab during the publication process for speedy dissemination of the nanomaterial data. This initiative will greatly enhance information exchange in the entire cancer nanotechnology community, accelerating further advances.”
Reciprocal linking between articles and data is one of Elsevier’s initiatives for sharing research data. Elsevier collaborates with more than forty data repositories, and is continually looking to collaborate with other relevant organizations.
Example articles with reciprocal caNanoLab-ScienceDirect linking:
- Guan YY, Luan X, Xu JR, Liu YR, Lu Q, Wang C, Liu HJ, Gao YG, Chen HZ, Fang C. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials. 35(9):3060-70 (2014). http://www.sciencedirect.com/science/article/pii/S0142961213015111 doi:10.1016/j.biomaterials.2013.12.027.
- Gaur S, Wang Y, Kretzner L, Chen L, Yen T, Wu X, Yuan YC, Davis M, Yen Y. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine. 10(7):1477-86 (2014). http://www.sciencedirect.com/science/article/pii/S1549963414001865 doi:10.1016/j.nano.2014.04.003.
- Khatun Z, Nurunnabi M, Reeck GR, Cho KJ, Lee YK. Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release 170:74-82 (2013). http://www.sciencedirect.com/science/article/pii/S0168365913002435 doi:10.1016/j.jconrel.2013.04.024.
The ten Elsevier journals with reciprocal caNanoLab-ScienceDirect linking are:
Biomaterials, Cancer Letters, European Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, Journal of Controlled Release, Materials Science and Engineering: C, Nanomedicine, Toxicology and Applied Pharmacology, Toxicology Letters, Ultrasound in Medicine and Biology (with more journals to come soon).
The cancer Nanotechnology Laboratory (caNanoLab) data portal is a curated resource of nanomaterial characterization data resulting from physico-chemical, in vitro, and in vivo assays. caNanoLab was developed as a collaboration between the US National Cancer Institute’s (NCI) Center for Biomedical Informatics and Information Technology (NCI CBIIT) and the NCI Office of Cancer Nanotechnology Research (NCI OCNR) as a resource for enabling nanotechnology data sharing in a secure fashion. Over 1,000 nanomaterial datasets are publically available in caNanoLab for review and re-use, with the goal of providing researchers with information that enables the acceleration of nanotechnology use in biomedicine.
ScienceDirect is Elsevier’s leading information solution that empowers over 15 million researchers, teachers, students, healthcare professionals and information professionals around the world to be more impactful in their work. ScienceDirect combines authoritative, full-text scientific, technical and health publications with smart, intuitive functionality so users can stay more informed, and can work more effectively and efficiently. With over 13 million publications from nearly 2,500 journals and over 33,000 books from Elsevier, our imprints and our society partners, ScienceDirect empowers smarter research.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Sr. Content Innovation Manager
+31 20 485 3197